What do systematic reviews say?

56 questions · 56 findings · 3 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 5.4%GRADE not reported 7 · 12.5%Very low 5 · 8.9%Low 18 · 32.1%Moderate 23 · 41.1%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- QUETIAPINE vs OLANZAPINE · Quality of life: general ‐ average change in endpoint score medium term QLS total score
  Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 286 participants
  Moderate
Direct match · question page
- QUETIAPINE vs OLANZAPINE · Mental state: 3. Negative symptoms ‐ endpoint score PANSS negative subscore
  Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 801 participants
  Moderate
Direct match · question page
- QUETIAPINE vs OLANZAPINE · Adverse effects: 3. Metabolic ‐ weight significant gain
  Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
  RR 0.69 [0.51, 0.95]
  7 studies · 1321 participants
  Moderate
Direct match · question page
- QUETIAPINE vs OLANZAPINE · Mental state: 1. General ‐ average endpoint score (PANSS total, high = poor)
  Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 1486 participants
  Low
Direct match · question page
- QUETIAPINE vs ARIPIPRAZOLE · Mental state: 1. General ‐ average endpoint score PANSS total
  Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 297 participants
  Low

QUETIAPINE vs ARIPIPRAZOLE

Mental state · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 297 participants
Low

QUETIAPINE vs CLOZAPINE ‐ all data short term

Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 142 participants
Low

QUETIAPINE vs CLOZAPINE ‐ all data short term

Quality of life: substantial improvement · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

QUETIAPINE vs CLOZAPINE ‐ all data short term

Adverse effects: 1. Sedation · schizophrenia

QUETIAPINE probably leads to lower adverse effects: 1. Sedation compared with CLOZAPINE ‐ all data short term (moderate certainty).

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.22 [0.11, 0.47]
2 studies · 135 participants
Moderate

QUETIAPINE vs CLOZAPINE ‐ all data short term

Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
Low

QUETIAPINE vs CLOZAPINE ‐ all data short term

Weight gain · schizophrenia

QUETIAPINE showed no clear difference in adverse effects: 3. Metabolic ‐ weight gain compared with CLOZAPINE ‐ all data short term (low certainty).

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.53 [0.25, 1.11]
2 studies · 135 participants
Low

QUETIAPINE vs OLANZAPINE

Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1486 participants
Low

QUETIAPINE vs OLANZAPINE

Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 801 participants
Moderate

QUETIAPINE vs OLANZAPINE

Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 801 participants
Moderate

QUETIAPINE vs OLANZAPINE

Quality of life (medium term: 12 months) · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 286 participants
Moderate

QUETIAPINE vs OLANZAPINE

Adverse effects: 1. Sedation · schizophrenia

QUETIAPINE showed no clear difference in adverse effects: 1. Sedation compared with OLANZAPINE (moderate certainty).

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.98 [0.84, 1.13]
7 studies · 1615 participants
Moderate

QUETIAPINE vs ARIPIPRAZOLE

Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 297 participants
Low

QUETIAPINE vs OLANZAPINE

Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1127 participants
Moderate

QUETIAPINE vs OLANZAPINE

Adverse effects: 3. Metabolic ‐ weight significant gain · schizophrenia

QUETIAPINE probably leads to lower adverse effects: 3. Metabolic ‐ weight significant gain compared with OLANZAPINE (moderate certainty).

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.69 [0.51, 0.95]
7 studies · 1321 participants
Moderate

QUETIAPINE vs PALIPERIDONE

Mental state · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 319 participants
Moderate

QUETIAPINE vs PALIPERIDONE

Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 319 participants
Moderate

QUETIAPINE vs PALIPERIDONE

Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 319 participants
Moderate

QUETIAPINE vs PALIPERIDONE

Quality of life: substantial improvement · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

QUETIAPINE vs PALIPERIDONE

Adverse effects: 1. Sedation · schizophrenia

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

QUETIAPINE vs PALIPERIDONE

Adverse effects: 2. Extrapyramidal effects ‐ use of antiparkinson medication · schizophrenia

QUETIAPINE probably leads to lower adverse effects: 2. Extrapyramidal effects use of antiparkinson… compared with PALIPERIDONE (moderate certainty).

1 finding from 1 review

Quetiapine versus other atypical antipsychotics for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.64 [0.45, 0.91]
1 study · 319 participants
Moderate